Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 3
2004 6
2005 3
2006 7
2007 6
2008 4
2009 3
2010 1
2011 2
2012 3
2013 3
2014 2
2016 1
2017 1
2018 3
2019 4
2020 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

53 results
Results by year
Filters applied: . Clear all
Page 1
Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation.
Bera TK. Bera TK. Biomolecules. 2020 Sep 29;10(10):1387. doi: 10.3390/biom10101387. Biomolecules. 2020. PMID: 33003418 Free PMC article. Review.
Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
Cerise A, Bera TK, Liu X, Wei J, Pastan I. Cerise A, et al. Among authors: bera tk. Clin Colorectal Cancer. 2019 Sep;18(3):192-199.e1. doi: 10.1016/j.clcc.2019.06.006. Epub 2019 Jul 2. Clin Colorectal Cancer. 2019. PMID: 31345777
Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity.
Zheng Z, Okada R, Kobayashi H, Nagaya T, Wei J, Zhou Q, Lee F, Bera TK, Gao Y, Kuhlman W, Tai CH, Pastan I. Zheng Z, et al. Among authors: bera tk. Mol Cancer Ther. 2020 Mar;19(3):812-821. doi: 10.1158/1535-7163.MCT-19-0890. Epub 2019 Dec 23. Mol Cancer Ther. 2020. PMID: 31871266 Free PMC article.
Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models.
Shancer Z, Liu XF, Nagata S, Zhou Q, Bera TK, Pastan I. Shancer Z, et al. Among authors: bera tk. Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4592-4598. doi: 10.1073/pnas.1821733116. Epub 2019 Feb 19. Proc Natl Acad Sci U S A. 2019. PMID: 30782819 Free PMC article.
Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma.
Shancer Z, Williams M, Igelman A, Nagata S, Ise T, Pastan I, Bera TK. Shancer Z, et al. Among authors: bera tk. Antib Ther. 2018 Jun;1(1):19-25. doi: 10.1093/abt/tby004. Epub 2018 Aug 20. Antib Ther. 2018. PMID: 30272049 Free PMC article.
Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy.
Bera TK, Liu W, Leshem J, King E, Kozlov S, Pastan I. Bera TK, et al. J Immunother. 2019 May;42(4):119-125. doi: 10.1097/CJI.0000000000000263. J Immunother. 2019. PMID: 30933045 Free PMC article.
Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity.
Wei J, Bera TK, Liu XF, Zhou Q, Onda M, Ho M, Tai CH, Pastan I. Wei J, et al. Among authors: bera tk. Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3501-E3508. doi: 10.1073/pnas.1721780115. Epub 2018 Mar 26. Proc Natl Acad Sci U S A. 2018. PMID: 29581296 Free PMC article.
An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.
Bera TK, Onda M, Kreitman RJ, Pastan I. Bera TK, et al. Leuk Res. 2014 Oct;38(10):1224-9. doi: 10.1016/j.leukres.2014.06.014. Epub 2014 Jul 5. Leuk Res. 2014. PMID: 25127689 Free PMC article.
Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia.
Müller F, Cunningham T, Beers R, Bera TK, Wayne AS, Pastan I. Müller F, et al. Among authors: bera tk. Toxins (Basel). 2018 May 21;10(5):210. doi: 10.3390/toxins10050210. Toxins (Basel). 2018. PMID: 29883379 Free PMC article.
Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
Awuah P, Bera TK, Folivi M, Chertov O, Pastan I. Awuah P, et al. Among authors: bera tk. Mol Cancer Ther. 2016 Jul;15(7):1648-55. doi: 10.1158/1535-7163.MCT-15-0863. Epub 2016 May 18. Mol Cancer Ther. 2016. PMID: 27196771 Free PMC article.
53 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page